Tracking organ damage over the first year after a diagnosis of granulomatosis with polyangiitis (GPA), the most common type of ANCA-associated vasculitis (AAV), predicts relapse risk more reliably than a single damage measurement early in the disease course, a study found. GPA patients whose cumulative damage score reached a…
News
A new study from Japan found that people with ANCA-associated vasculitis (AAV) have significantly higher levels of a protein known as AIM, fully apoptosis inhibitor of macrophage, in their urine than individuals without this vasculitis type — and these levels may be a useful way to monitor an individual’s…
Six-month remission rates with biosimilar versions of rituximab were similar to those seen with the original therapy among adults with the two most common types of ANCA-associated vasculitis (AAV), according to a real-world study in Canada. Data also showed no significant differences in serious adverse events or AAV-related…
The presence of clumps of inflammatory cells, or granulomas, in the liver is a rare manifestation of ANCA-associated vasculitis (AAV) that varies widely and can be difficult to diagnose, according to the findings of a new study from Tunisia. While liver problems are common in AAV, the researchers noted…
Free-floating CD95L, a protein involved in inflammation and immune responses, is found at significantly higher levels in the blood of people with ANCA-associated vasculitis (AAV) and may be a potential treatment target, according to a study in France. Through a detailed series of experiments, researchers figured out that CD95L…
Mirador Therapeutics has secured worldwide development and commercialization rights to KP-301, an experimental long-acting antibody therapy licensed from Kira Pharmaceuticals, and plans to develop it for ANCA-associated vasculitis (AAV). KP-301 is a long-acting antibody that blocks C5a, a protein in the complement system that helps drive inflammation and small…
Kidney biopsy findings may help identify which adults with severe kidney involvement due to ANCA-associated vasculitis (AAV) are more likely to recover kidney function after treatment, a small study suggests. Data showed that patients with better kidney function at one year had a higher percentage of normal glomeruli —…
Hearing loss is common among people with two types of ANCA-associated vasculitis (AAV), affecting half of those assessed in a small study in Saudi Arabia, according to researchers. Following audiological and other assessments, the team found loss of hearing in about 50% of participants with granulomatosis with polyangiitis (GPA)…
A study linked higher blood levels of tiny sacs carrying immune proteins from the complement system — which is known to contribute to ANCA-associated vasculitis (AAV) — to kidney involvement and damage in AAV patients. The findings could help doctors detect kidney disease in people with AAV and develop…
The U.S. Food and Drug Administration (FDA) has cleared the start of clinical testing of FT839, Fate Therapeutics’ experimental off-the-shelf CAR T-cell therapy for ANCA-associated vasculitis (AAV) and other autoimmune disorders. The company plans to launch a basket Phase 1/2 clinical trial to evaluate FT839 in combination with…
Recent Posts
- New resource offers a road map for navigating ANCA-associated vasculitis
- Tracking organ damage after GPA diagnosis predicts relapse risk
- Levels of AIM protein in urine may help in tracking vasculitis treatments
- What you should know about Medicare and inpatient vs. outpatient care
- Biosimilar therapy shows similar 6-month remission rates in AAV